Third Arc Bio is a technology company.
Third Arc Bio has raised $222.0M across 2 funding rounds.
Third Arc Bio has raised $222.0M in total across 2 funding rounds.
Third Arc Bio has raised $222.0M in total across 2 funding rounds.
Third Arc Bio's investors include Andreessen Horowitz, AbbVie, Aberdeen Investments, Alderline Group, Biotechnology Value Fund, Galapagos, Goldman Sachs Alternatives, Hillhouse Investment, Marshall Wace, Omega Funds, T. Rowe Price, Sofinnova Investments.
Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells, targeting solid tumors and immunology & inflammation (I&I) diseases.[1][2][3][4] Its drug development engine leverages a solid tumor synergy platform and an I&I platform for tissue-specific immune regulation, aiming for superior efficacy and safety in best-in-class biologics.[1][3][4] Launched in 2022 with seed funding from Omega Funds, the company secured an oversubscribed $165 million Series A in July 2024, led by Vida Ventures with participation from Cormorant Asset Management, Hillhouse Investment, and others, funding multiple programs entering the clinic in early 2025.[3][4][5] Key momentum includes dosing the first patient in its lead T cell engager program, ARC101.[2]
Third Arc Bio was seeded by Omega Funds and formally launched in 2022, with roots tracing to 2021 and founded by CSO Sanjaya Singh, PhD.[3][4][6] The leadership team expanded with CEO Peter F. Lebowitz, MD, PhD (joined January 2024, former global head of Oncology R&D at Johnson & Johnson), and Joe Erhardt, PhD, bringing collective experience in advancing 19 drugs to market.[4][5] The idea emerged from innovating the "Third Arc" of antibody therapeutics, unlocking immune synapse biology for complex diseases like solid tumors and autoimmune conditions, building on the team's track record in oncology and I&I standards-of-care.[2][4]
Third Arc Bio rides the wave of T cell engager therapies expanding from hematological cancers to solid tumors and autoimmune diseases, where engineered immune modulation addresses unmet needs in efficacy and safety.[2][4][5] Timing aligns with hundreds of clinical programs validating "living drug" modalities, amplified by post-2024 funding amid biotech recovery.[4][5] Market forces favor its synapse-focused biologics amid demand for precision immune regulation, influencing the ecosystem by redefining antibody tech's third evolution and accelerating T cell biology applications.[2][3]
Multiple IND filings in 2025 position Third Arc Bio for clinical data readouts, potentially validating its platforms in solid tumors and I&I.[3][4] Trends like AI-optimized biologics and combo regimens will shape progress, with the team's track record suggesting influence growth through partnerships or approvals. As T cell engagers mature, Third Arc could redefine standards, powering superior immune synapses for complex diseases.[2][4][5]
Third Arc Bio has raised $222.0M across 2 funding rounds. Most recently, it raised $52.0M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 4, 2026 | $52.0M Series A | Andreessen Horowitz | AbbVie, Aberdeen Investments, Alderline Group, Biotechnology Value Fund, Galapagos, Goldman Sachs Alternatives, Hillhouse Investment, Marshall Wace, Omega Funds, T. Rowe Price |
| Jul 1, 2024 | $170.0M Series A | Sofinnova Investments, Vida Ventures |